Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 25;23(23):14775.
doi: 10.3390/ijms232314775.

The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy

Linyinxue Dong  1   2 , Xuechen Tian  1   2 , Yunqi Zhao  1   2   3 , Haohong Tu  3 , Aloysius Wong  1   2   3 , Yixin Yang  1   2   3   4
Affiliations

The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy

Linyinxue Dong et al. Int J Mol Sci. .

Abstract

Melanoma is the most aggressive form of skin cancer, characterized by life-threatening and rapidly spreading progression. Traditional targeted therapy can alleviate tumors by inactivating hyperactive kinases such as BRAF or MEK but inevitably encounters drug resistance. The advent of immunotherapy has revolutionized melanoma treatment and significantly improved the prognosis of melanoma patients. MicroRNAs (miRNAs) are intricately involved in innate and adaptive immunity and are implicated in melanoma immunotherapy. This systematic review describes the roles of miRNAs in regulating the functions of immune cells in skin and melanoma, as well as the involvement of miRNAs in pharmacology including the effect, resistance and immune-related adverse events of checkpoint inhibitors such as PD-1 and CTLA-4 inhibitors, which are used for treating cutaneous, uveal and mucosal melanoma. The expressions and functions of miRNAs in immunotherapy employing tumor-infiltrating lymphocytes and Toll-like receptor 9 agonists are also discussed. The prospect of innovative therapeutic strategies such as the combined administration of miRNAs and immune checkpoint inhibitors and the nanotechnology-based delivery of miRNAs are also provided. A comprehensive understanding of the interplay between miRNAs and immunotherapy is crucial for the discovery of reliable biomarkers and for the development of novel miRNA-based therapeutics against melanoma.

Keywords: immune checkpoint inhibitor; immunotherapy; melanoma; miRNA (microRNA).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Number of miRNA related publications in the past ten years (data obtained from PubMed).
Figure 2
Figure 2
The roles of miRNA in the innate and adaptive immune systems. The miRNAs in black are oncogenic while those in red are tumor-suppressive.
See this image and copyright information in PMC

References

    1. Stewart B.W., Kleihues P. World Cancer Report. IARC Press; Lyon, France: 2003.
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics. CA-Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Lasithiotakis K., Leiter U., Kruger-Krasagakis S., Tosca A., Garbe C. Comparative analysis of incidence and clinical features of cutaneous malignant melanoma in Crete (Greece) and southern Germany (central Baden-Wurttemberg) Br. J. Dermatol. 2006;154:1123–1127. doi: 10.1111/j.1365-2133.2006.07163.x. - DOI - PubMed
    1. Allais B.S., Beatson M., Wang H.K., Shahbazi S., Bijelic L., Jang S., Venna S. Five-year survival in patients with nodular and superficial spreading melanomas in the US population. J. Am. Acad. Dermatol. 2021;84:1015–1022. doi: 10.1016/j.jaad.2020.11.047. - DOI - PubMed
    1. Coit D.G., Thompson J.A., Albertini M.R., Barker C., Carson W.E., Contreras C., Daniels G.A., DiMaio D., Fields R.C., Fleming M.D., et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2019;17:367–402. doi: 10.6004/jnccn.2019.0018. - DOI - PubMed

Publication types